Bridgebio Oncology Therapeutics Inc (BBOT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | |
| Operating Expenses | 19,664 |
| Operating Income | -19,664 |
| Other Income | 2,341 |
| Pre-tax Income | -17,323 |
| Net Income Continuous | -17,323 |
| Net Income | $-17,323 |
| EPS Basic Total Ops | -1,562.18 |
| EPS Basic Continuous Ops | -1,562.18 |
| EPS Diluted Total Ops | -1,562.18 |
| EPS Diluted Continuous Ops | -1,562.18 |
| EBITDA(a) | $-19,664 |